BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · IEX Real-Time Price · USD
+0.59 (0.77%)
At close: May 17, 2024, 4:00 PM
-1.55 (-2.00%)
After-hours: May 17, 2024, 7:09 PM EDT

Company Description

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.

The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.

BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical logo
Country United States
Founded 1996
IPO Date Jul 23, 1999
Industry Biotechnology
Sector Healthcare
Employees 3,401
CEO Alexander Hardy

Contact Details

105 Digital Drive
Novato, California 94949
United States
Phone (415) 506-6700

Stock Details

Ticker Symbol BMRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001048477
CUSIP Number 09061G101
ISIN Number US09061G1013
Employer ID 68-0397820
SIC Code 2834

Key Executives

Name Position
Brian R. Mueller Chief Financial Officer and Executive Vice President
George Eric Davis Executive Vice President, Chief Legal Officer, General Counsel and Secretary
Jeffrey Robert Ajer Executive Vice President and Chief Commercial Officer
Dr. Henry J. Fuchs M.D., Ph.D. President of Worldwide Research and Development
Alexander Hardy President, Chief Executive Officer and Director
Erin Burkhart Group Vice President and Chief Accounting Officer
Dr. C. Greg Guyer Ph.D. Executive Vice President and Chief Technical Officer
Dr. Kevin Eggan Ph.D. Chief Scientific Officer and Senior Vice President of Research and Early Development
Traci McCarty Group Vice President of Investor Relations
Humaira Serajuddin Senior Vice President and Chief Marketing Officer

Latest SEC Filings

Date Type Title
May 14, 2024 8-K Current Report
May 10, 2024 144 Filing
May 9, 2024 144 Filing
May 2, 2024 144 Filing
May 2, 2024 144 Filing
Apr 26, 2024 10-Q Quarterly Report
Apr 24, 2024 8-K Current Report
Apr 23, 2024 8-K Current Report
Apr 12, 2024 144 Filing
Apr 11, 2024 144 Filing